IMMUNITYBIO INC (IBRX) Stock Analyst Ratings
NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to IBRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 14.54. This target is 365.87% above the current price.
IBRX was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about IBRX.
In the previous month the buy percentage consensus was at a similar level.
IBRX was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-01-16 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-01-10 | BTIG | Initiate | Buy |
| 2025-01-06 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-12-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-11-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2024-10-23 | EF Hutton | Initiate | Buy |
| 2024-08-19 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-04-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-03-25 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2023-05-12 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-08-03 | Jefferies | Initiate | Buy |